Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology

CAMBRIDGE--()--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that data from four abstracts from the Company’s clinical development program in support of tazemetostat for use in non-Hodgkin lymphoma (NHL) will be presented during the American Society of Hematology Meeting on Lymphoma Biology, to be held in Colorado Springs, CO, from June 18 to June 21, 2016.

Tazemetostat is a first-in-class EZH2 inhibitor currently in phase 2 studies in advanced B-cell non-Hodgkin lymphoma (NHL) and certain genetically defined solid tumors. Among the data to be presented is the first interim report from the Company’s ongoing phase 2 study in patients with NHL.

Planned Presentations:

Oral Presentation: EZH2 as a target for non-Hodgkin lymphoma and beyond: tazemetostat experience; from bench to bedside and back to the bench
Speaker: Vincent Ribrag, MD, Institut Gustave-Roussy, Paris, France
Session Title: Exciting New Mechanisms-Targeted Therapies and Clinical Trials
Date: June 21, 2016
Time: 10:20 a.m. – 10:50 a.m. Mountain Time

Poster: Tazemetostat treatment drives wild-type and mutant EZH2 DLBCL cell lines to a cell fate decision between apoptosis or differentiation (Poster #39)
Author: Michael Thomenius, Ph.D., Epizyme
Date: June 19, 2016
Time: 3:45 p.m. – 5:15 p.m. Mountain Time

Poster: Initial report from a phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Poster #98)
Author: Franck Morschhauser, MD, PhD, Centre Hospitalier Régional Universitaire de Lille, Lille, France
Date: June 20, 2016
Time: 3:45 p.m. – 5:15 p.m. Mountain Time

Poster: Chromatin flow cytometry based assessment of H3K27me3 pharmacodynamics in blood from diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients following exposure to the EZH2 inhibitor tazemetostat reveals disparate response profiles in specific PMBC subpopulations (Poster #38)
Author: Christopher Plescia, Epizyme
Date: June 20, 2016
Time: 3:45 p.m. – 5:15 p.m. Mountain Time

About the Tazemetostat Clinical Trial Program
Tazemetostat, a first-in-class EZH2 inhibitor, is currently being studied in ongoing phase 2 programs in both non-Hodgkin lymphoma and certain genetically defined solid tumors, including INI1-negative and SMARCA4-negative tumors and synovial sarcoma.

The Company has announced plans to initiate additional clinical evaluations of tazemetostat in 2016, including both a combination study with R-CHOP and a combination study with an immune checkpoint inhibitor in patients with NHL, as well as a monotherapy study in patients with mesothelioma.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc. and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plans," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation of future clinical studies or expansion of ongoing clinical studies, availability and timing of data from ongoing clinical studies, whether preclinical data and results from clinical trials will be predictive of the results of future trials, whether the Company’s collaborations will be successful, expectations for regulatory approvals, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates or companion diagnostics and other factors discussed in the "Risk Factors" section of our Form 10-Q most recently filed with the SEC, and in our other filings from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Contacts

Investors:
Rebecca Cohen, 617-401-0722
Epizyme, Inc.,
Investor Relations and Corporate Communications
rcohen@epizyme.com
Media:
Michael Lampe, 484-575-5040
Scient Public Relations
michael@scientpr.com

Epizyme, Inc.